Robert Hollingsworth

Robert Hollingsworth

Company: Shoreline Biosciences

Job title: Chief Scientific Officer


Bringing Novel Gene Engineering Techniques Through IND-Enabling Studies to Communicate Safety & Applications to Regulators 4:50 pm

Ensuring novel engineering technologies aren’t causing unexpected toxicity, off-target effects, or malignancy, and bringing safety data to regulators to communicate safety of novel tools Managing GMP expectations for IND-enabling studies which include novel editing technologies Sharing key considerations for developers looking to use new editing tools in their pipelinesRead more

day: Day One

Sharing Preclinical Findings of Next-Generation iPSC-Derived NK Therapy 11:00 am

Discussing the mechanisms and therapeutic benefits of multiplexed CRISPR-edited iPSC-derived NK cells Outlining next steps with engineered macrophage therapies and the clinical utility of each approach Overcoming tumor immunosuppression with rational drug design and choice of engineering approachesRead more

day: Next-Generation Engineering Focus Day
day: Pre-Conference Day Track A AM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.